Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Masked, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of G01 Eye Drops in the Treatment of Optic Nerve Injury Associated With Open-Angle Glaucoma

NCT07777861 is registered in ClinicalTrials.gov with Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. as lead sponsor.

NCT NCT07777861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07777861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Masked, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of G01 Eye Drops in the Treatment of Optic Nerve Injury Associated With Open-Angle Glaucoma
Lead sponsor
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2026
Completion date
December 1, 2027
Enrollment
90 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

optic nerve injury, primary open-angle glaucoma